ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
 PMID: 27130466       2016       Retrovirology
Result: 3a, b, f), or undetectable levels in H51Y/R263K-K103N, H51Y/R263K-E138K and H51Y/R263K-M184I viruses.
Result: Our results show that the addition of R263K to the K65R-, L74V-, K103N-, E138K-, or M184I/V-harbouring viruses resulted in further moderate decreases in viral infectivity ranging from 1.23-fold to 3.17-fold (P < 0.05), depending on the RT backbone.
Result: The addition of DTG-resistance substitutions redu


  [The prevalence of primary HIV-1 drug resistance in newly reported HIV infections in Henan].
 PMID: 27188354       2016       Zhonghua liu xing bing xue za zhi
Abstract: M184V/I(2.08%)and K103N/S(2.88%)were the most commonly emerged NRTI and NNRTI resistance mutation.


  Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
 PMID: 27231099       2016       Journal of the International AIDS Society
Result: Other common (>20%) RT mutations were NRTI-associated M184V/I (27/35, 77%) and NNRTI-associated Y181C/G/Y (22/35, 63%), G190A/S (13/35, 37%) and K103N/S (11/35, 31%).
Table: M184I


  Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
 PMID: 27231280       2016       The Journal of antimicrobial chemotherapy
Abstract: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate RAMs studied were K65R, L100I, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C and M230I/L in the RT.


  Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase.
 PMID: 27241734       2016       Biomedical and environmental sciences
Abstract: The mutations M184I and M230I were more prevalent in proviral DNA than in viral RNA (Fisher's exact test, P<0.05).


  Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting.
 PMID: 27333000       2016       PloS one
Discussion: All studies reporting resistance mutations in this time period identified the reverse transcriptase M184V/I mutation.


  Genotypic HIV-1 Drug Resistance Among Patients Failing Tenofovir-Based First-Line HAART in South India.
 PMID: 27334566       2016       AIDS research and human retroviruses
Abstract: The predominant NRTI and NNRTI mutations observed were M184IV (59.9%), K65R (28.1%), and thymidine analogue mutations (TAMs, 29.3%) and K103NS (54.5%), V106AM (39.5%), and Y181CIV (19.8%), respectively.


  Rapid In Vitro Evaluation of Antiretroviral Barrier to Resistance at Therapeutic Drug Levels.
 PMID: 27356854       2016       AIDS research and human retroviruses
Abstract: At high multiples of its CCE Cmin, emtricitabine (FTC) selected for the rapid emergence of M184I/V, a result consistent with resistance emergence in vivo.


  High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
 PMID: 27367488       2016       AIDS (London, England)
Abstract: DESIGN: The objective of this study was to determine the effects of the M184I/V and K65R substitutions in reverse transcriptase on the ability of HIV-1 to become resistant against RAL, EVG or DTG.
Abstract: In such cases, common resistance substitutions in reverse transcriptase that were associated with nucleos(t)ide reverse transcriptase inhibitors included M184I/V and K65R and these occurred together with various mutations in integrase.
Abstract: METHODS: We performed tissue culture selection experiments using reverse transcriptase inhibitor-resistant viruses containing resistance substitutions at positions K65R


  Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.
 PMID: 27631260       2016       Medicine
Result: The most common NRTI and NNRTI mutation were M184V/I (51.25%) and K103N (36.25%), respectively.



Browser Board

 Co-occurred Entities




   Filtrator